The Act creates a positive balance between government interests to save money and the interests of Medicare recipients to receive a wide range of drugs for their specific needs. The current ban on government negotiations with pharmaceutical companies serves to protect Medicate recipients by using the positives of the free market, such as the experience and purchasing power of PBMs. While there are serious potential problems with this approach,

Prescriptions are everywhere, and even adult prescriptions are easily accessed by youth abusing the wide variety of drugs. The 2003 National Survey on Drug Use and Health (NSDUH) found four percent of America's youth "ages 12 to 17 reported nonmedical use of prescription medications in the past month," (National Institute on Drug Abuse 1). Children given medications at a young age also have a greater chance of developing later

Drug costs have gone from 26% of health care spending by private insurance companies in 1990 to 44% in 2006 (Kaiser Foundation, 2008). This issue has not been adequately addressed by health care reform. Instead, a deal appears to be made for $80 billion in concessions from the pharmaceutical industry in exchange for its support of health care reform (Kirkpatrick, 2009). The underlying trend in each of these major issues

Nursing Leadership Health Policy Health Policy Change The health policy change encompasses Medicare Part D. Medicare D. is also referred to as the Medicare prescription drug benefit. It is part of the Medicare program that is purposed to bankroll the cost of prescription drugs together with coverage payments for prescription drugs for Medicare recipients (Centers for Medicare & Medicaid Services, 2016). The proposed policy change with respect to Medicare Part D is

OTC and Prescription Drugs Curbing the Power of Drugs Everyone knows about the enslaving effects of substance abuse and addiction. By now, everyone knows that addiction is a compulsive physical or psychological to take in more and more of a particular substance despite knowing its harm (Alta Mira 2013). Once the use of an addicting substance is begun and continued, it only takes some time to reach a point when quitting becomes

Pharmacy Ethics The author of this report has been asked to review the legal and ethical considerations in play given the test case scenario surrounding Pharmacare and Compcare. As is quickly apparent while reading the case study, the company engaged in a long and extensive list of ethical and/or legal violations as a means to maximize profit and minimize the legal and other red tape that seems to bother them even